Literature DB >> 25749710

Staphylococcus aureus dry stress survivors have a heritable fitness advantage in subsequent dry exposure.

Lisa Maudsdotter1, Saki Imai2, Ryosuke L Ohniwa2, Shinji Saito2, Kazuya Morikawa3.   

Abstract

Staphylococcus aureus is a major cause of hospital-acquired infections. The ability to survive on abiotic surfaces is an important characteristic that facilitates transmission between human hosts. We found that S. aureus survivors of dry surface incubation are resistant to subsequent dry stress exposure. Survivors also had reduced sensitivity to the disinfectant chlorhexidine gluconate, but not to ethanol. By using a set of mutants in cardiolipin synthase genes, we further demonstrated that the housekeeping cardiolipin synthase, Cls2, was significant for survival on dry surface. Taken together, this study provides insights into S. aureus survival outside of a host.
Copyright © 2015 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Adaptation; Cardiolipin; Dry stress; Staphylococcus aureus; Transmission

Mesh:

Substances:

Year:  2015        PMID: 25749710     DOI: 10.1016/j.micinf.2015.02.004

Source DB:  PubMed          Journal:  Microbes Infect        ISSN: 1286-4579            Impact factor:   2.700


  3 in total

1.  Identification of nucleoid associated proteins (NAPs) under oxidative stress in Staphylococcus aureus.

Authors:  Yuri Ushijima; Ryosuke L Ohniwa; Kazuya Morikawa
Journal:  BMC Microbiol       Date:  2017-10-02       Impact factor: 3.605

Review 2.  What Happens in the Staphylococcal Nucleoid under Oxidative Stress?

Authors:  Kazuya Morikawa; Yuri Ushijima; Ryosuke L Ohniwa; Masatoshi Miyakoshi; Kunio Takeyasu
Journal:  Microorganisms       Date:  2019-11-29

3.  Effect of thermal control of dry fomites on regulating the survival of human pathogenic bacteria responsible for nosocomial infections.

Authors:  Tomoko Shimoda; Torahiko Okubo; Yoshiki Enoeda; Rika Yano; Shinji Nakamura; Jeewan Thapa; Hiroyuki Yamaguchi
Journal:  PLoS One       Date:  2019-12-27       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.